Comparison of prostate-specific antigen (PSA) measured by four combinations of free PSA and total PSA assays

Clinical Chemistry

Volumn 43, Issue 9, 1997, Pages 1588-1594

  Junker, Ralf ^a   Brandt, Burkhard ^a   Zechel, Christian ^a   Assmann, Gerd ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; PROSTATE CANCER; PROSTATE HYPERTROPHY;

EID: 0030809761     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/43.9.1588     Document Type: Article

References (15)

1. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostatespecific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990;194:755-63.
2. Watt KW, Lee PJ, M'Timkulu T, Chan WP, Loor R. Human prostatespecific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci U S A 1986:83:3166-70.
3. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979:17:159-63.
4. Smith MR, Biggar S, Hussain M. Prostate-specific antigen messenger RNA is expressed in non-prostate cells: implications for detection of micrometastases. Cancer Res 1995:55:2640-44.
5. Wang MC, Papsidero MC, Kuriyama M, Valenzuela LA, Murphy GP, Chu TM. Prostate antigen: a new potential marker for prostate cancer. Prostate 1981:2:89-96.
6. Ruckle HC, Klee GG, Oesterling JE. Prostate specific antigen: concepts for staging prostate cancer and monitoring response to therapy. Mayo Clin Proc 1994;69:69-79.
7. Glenski WJ, Malek RS, Myrtle JF, Oesterling JE. Sustained, substantially increased concentration of prostate-specific antigen in the absence of prostatic malignant disease: an unusual clinical scenario. Mayo Clin Proc 1992;67:249-52.
8. 1-antichymotrypsin. Clin Chem 1991:37:1618-25.
9. 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993:150:100-5.
10. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-6.
11. Luderer AA, Chen YT, Soriano TF, Kramp WJ, Carlson G, Cuny-C, et al. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 1995;46:187-94.
12. Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274:1214-20.
13. Semjonow A, Hamm M, Rathert P, Hertle L. Prostate-specific antigen corrected for prostate volume improves differentiation of benign prostatic hyperplasia and organ-confined prostatic cancer. Br J Urol 1994:73:538-43.
14. 1-antichymotrypsin: potential reference material for international standardization of PSA immunoassays. Clin Chem 1995;41:1273-82.
15. 1-L-Antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urology 1994:43:427-34.